STAT

Opinion: NIH needs to raise the bar for funding alternative medicine research

The NIH needs a new way to review — and fund — alternative medicine grant proposals.
The National Center for Complementary and Integrative Health, part of the NIH, has supported studies such as "Long-Term Chamomile Therapy of Generalized Anxiety Disorder."

Suppose you needed to have a CT scan for a sudden, severe headache and partial loss of vision and your doctor asked a nutritionist to read it, rather than a radiologist. Would you trust the diagnosis? Evaluation by a different — and what most would consider a lesser — standard is essentially how a significant amount of research funding is approved by one component of the National Institutes of Health.

Let me step back for a minute before plunging ahead. Federally funded scientific research runs the gamut from studies of basic physical and biological processes to the. Government funding is especially essential for providing the scientific knowledge that underlies new medical treatments. The NIH, the nation’s major funder of nonmilitary research, has generally been a reliable supporter of high-quality research, conducted at its Bethesda, Md., campus and at universities and research institutes across the U.S.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Approval For Sarepta Drug, MSF Closing Access Campaign And More
After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a controversial, long-running saga:
STAT2 min read
STAT+: Pharmalittle: We’re Reading About EMA Plans For GLP-1 Shortages, Walgreens Store Closings, And More
The European Medicines Agency and member countries announced several steps to address shortages of GLP-1 drugs.

Related